On Thursday, Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.03 or -1.26% from the prior close of $2.39. The stock opened at $2.43 and ...

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and 80, diagnosed with Parkinson’s for less than three years.

Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.46 which represents a slight increase of $0.16 or 6.96% from the prior close of $2.3. The stock opened at $2.66 and ...

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...

Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...

Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...

For the past few years, Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while ...